We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 374

Myriad set for another round

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • September 29 2014

On Monday October 6th, the U.S. Court of Appeals for the Federal Circuit will entertain oral argument in another case involving Myriad's BRCA1BRCA2

Federal Circuit applies "searching review" of stay pending CBM proceeding

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • September 29 2014

In Benefit Funding Systems, LLC v. Advance America Cash Advance Centers, Inc., the Federal Circuit upheld the district court's decision to stay

Irreparable harm no longer presumed in the Third Circuit for Lanham Act plaintiffs

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • September 23 2014

In a recent decision, the Court of Appeals for the Third Circuit eliminated the presumption of irreparable harm for Lanham Act plaintiffs seeking

Court finds patent indefiniteness in unobtrusive claims

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • September 15 2014

In Interval Licensing LLC v. AOL, Inc., the Federal Circuit applied the test for patent indefiniteness set forth in the recent Supreme Court decision

Federal Circuit frames test for patent-eligibility

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • September 8 2014

Personalized medicine relies on diagnostics to analyze a patient for individualized therapy and for monitoring a patient's health status. Some

Australia upholds patent eligibility of isolated DNA

  • Foley & Lardner LLP
  • -
  • Australia
  • -
  • September 8 2014

The Full Federal Court of Australia affirmed that isolated nucleic acids, i.e. whether it be DNA or RNA, are patentable subject matter in Australia

Federal Circuit finds Apotex ANDAs do not infringe Lysteda patents

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • September 2 2014

In two decisions issued under the same name (Ferring B.V. V. Watson Laboratories, Inc.), the Federal Circuit upheld the validity of the Orange

Federal Circuit upholds validity of Lysteda patents

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 28 2014

In two decisions issued under the same name (Ferring B.V. V. Watson Laboratories, Inc.), the Federal Circuit upheld the validity of the Orange

Humira patent invalid for obviousness type double patenting

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 25 2014

In AbbVie Inc. v. Kennedy Institute of Rheumatology Trust, the Federal Circuit affirmed the district court's finding that a second patent covering

Will the USPTO respond to public feedback of its eligibility guidance?

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 25 2014

Periodically, the USPTO holds open meetings with the public to discuss its thinking on current topics relating to the patent procurement process